{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:28:41Z","timestamp":1790303321500,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82202200"],"award-info":[{"award-number":["No. 82202200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00259-023-06470-3","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T04:02:25Z","timestamp":1697860945000},"page":"871-882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"51","author":[{"given":"Jie","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huipan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-1813","authenticated-orcid":false,"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"key":"6470_CR1","first-page":"2674","volume":"5","author":"SS Chang","year":"1999","unstructured":"Chang SS, O\u2019Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674\u201381.","journal-title":"Clin Cancer Res"},{"key":"6470_CR2","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","volume":"42","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976\u201383. https:\/\/doi.org\/10.1007\/s00259-015-3125-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6470_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"6470_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"6470_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"6470_CR6","unstructured":"FDA Approves Pluvicto for Metastatic Castration-Resistant Prostate Cancer|FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. Accessed 13 Oct 2023."},{"key":"6470_CR7","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","volume":"29","author":"Z Wang","year":"2018","unstructured":"Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, et al. Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors. Bioconjug Chem. 2018;29:3213\u201321. https:\/\/doi.org\/10.1021\/acs.bioconjchem.8b00556.","journal-title":"Bioconjug Chem"},{"key":"6470_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","volume":"46","author":"J Zang","year":"2019","unstructured":"Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148\u201358. https:\/\/doi.org\/10.1007\/s00259-018-4096-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6470_CR9","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2967\/jnumed.120.242263","volume":"61","author":"J Zang","year":"2020","unstructured":"Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, et al. (177)Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:1772\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.242263.","journal-title":"J Nucl Med"},{"key":"6470_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2967\/jnumed.122.264857","volume":"64","author":"G Wang","year":"2023","unstructured":"Wang G, Zang J, Jiang Y, Liu Q, Sui H, Wang R, et al. A single-arm, low-dose, prospective study of (177)Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2023;64:611\u20137. https:\/\/doi.org\/10.2967\/jnumed.122.264857.","journal-title":"J Nucl Med"},{"key":"6470_CR11","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","volume":"50","author":"X Wen","year":"2023","unstructured":"Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, et al. Development of [(177)Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023;50:2846\u201360. https:\/\/doi.org\/10.1007\/s00259-023-06229-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6470_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/cncr.24797","volume":"116","author":"L Ferrer","year":"2010","unstructured":"Ferrer L, Kraeber-Bodere F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 2010;116:1093\u2013100. https:\/\/doi.org\/10.1002\/cncr.24797.","journal-title":"Cancer"},{"key":"6470_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR, Chen X, Muller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63:1199\u2013207. https:\/\/doi.org\/10.2967\/jnumed.121.262713.","journal-title":"J Nucl Med"},{"key":"6470_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"6470_CR15","doi-asserted-by":"publisher","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-50S. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","DOI":"10.2967\/jnumed.108.057307"},{"key":"6470_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jconrel.2022.11.034","volume":"353","author":"P Famta","year":"2023","unstructured":"Famta P, Shah S, Jain N, Srinivasarao DA, Murthy A, Ahmed T, et al. Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics. J Control Release. 2023;353:166\u201385. https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.034.","journal-title":"J Control Release"},{"key":"6470_CR17","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1021\/acs.bioconjchem.6b00487","volume":"27","author":"O Jacobson","year":"2016","unstructured":"Jacobson O, Kiesewetter DO, Chen X. Albumin-binding Evans Blue derivatives for diagnostic imaging and production of long-acting therapeutics. Bioconjug Chem. 2016;27:2239\u201347. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00487.","journal-title":"Bioconjug Chem"},{"key":"6470_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/MNM.0000000000001535","volume":"43","author":"A Nautiyal","year":"2022","unstructured":"Nautiyal A, Jha AK, Mithun S, Rangarajan V. Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review. Nucl Med Commun. 2022;43:369\u201377. https:\/\/doi.org\/10.1097\/MNM.0000000000001535.","journal-title":"Nucl Med Commun"},{"key":"6470_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85\u201390. https:\/\/doi.org\/10.2967\/jnumed.116.183194.","journal-title":"J Nucl Med"},{"key":"6470_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42\u201351. https:\/\/doi.org\/10.1007\/s00259-015-3174-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6470_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2967\/jnumed.119.236414","volume":"61","author":"J Violet","year":"2020","unstructured":"Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of (177)Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:857\u201365. https:\/\/doi.org\/10.2967\/jnumed.119.236414.","journal-title":"J Nucl Med"},{"key":"6470_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s00259-016-3609-9","volume":"44","author":"L Scarpa","year":"2017","unstructured":"Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, et al. The (68)Ga\/(177)Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV(max) values and absorbed dose estimates. Eur J Nucl Med Mol Imaging. 2017;44:788\u2013800. https:\/\/doi.org\/10.1007\/s00259-016-3609-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6470_CR23","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006\u201313. https:\/\/doi.org\/10.2967\/jnumed.115.168443.","journal-title":"J Nucl Med"},{"key":"6470_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2967\/jnumed.116.178483","volume":"58","author":"S Okamoto","year":"2017","unstructured":"Okamoto S, Thieme A, Allmann J, D\u2019Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for (177)Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017;58:445\u201350. https:\/\/doi.org\/10.2967\/jnumed.116.178483.","journal-title":"J Nucl Med"},{"key":"6470_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","volume":"48","author":"V Kramer","year":"2021","unstructured":"Kramer V, Fernandez R, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2021;48:893\u2013903. https:\/\/doi.org\/10.1007\/s00259-020-05022-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6470_CR26","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s00259-017-3751-z","volume":"44","author":"A Brauer","year":"2017","unstructured":"Brauer A, Grubert LS, Roll W, Schrader AJ, Schafers M, Bogemann M, et al. (177)Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1663\u201370. https:\/\/doi.org\/10.1007\/s00259-017-3751-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6470_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00259-019-04530-1","volume":"47","author":"Q Liu","year":"2020","unstructured":"Liu Q, Cheng Y, Zang J, Sui H, Wang H, Jacobson O, et al. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47:947\u201357. https:\/\/doi.org\/10.1007\/s00259-019-04530-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6470_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12885-023-10725-5","volume":"23","author":"ECA van der Sar","year":"2023","unstructured":"van der Sar ECA, Braat A, van der Voort-van Zyp JRN, van der Veen BS, van Leeuwen PJ, de Vries-Huizing DMV, et al. Tolerability of concurrent external beam radiotherapy and [(177)Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment na\u00efve patients, phase I study (PROQURE-I trial). BMC Cancer. 2023;23:268. https:\/\/doi.org\/10.1186\/s12885-023-10725-5.","journal-title":"BMC Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06470-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T09:05:04Z","timestamp":1705568704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06470-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6470"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06470-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,21]]},"assertion":[{"value":"19 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institute Review Board of the First Affiliated Hospital of Fujian Medical University (MRCTA, ECFAH of FMU[2023]004), Peking Union Medical College Hospital (JS2105), the Affiliated Hospital of Southwest Medical University (KY2022239), and the First Affiliated Hospital of Xiamen University (XMFHIIT-2023SL037-02), and this study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}